Company

Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed

Nov 6, 2026 · 08:02 AM ET· updated 1h ago

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative

Why It Matters

Acrivon bought a new medicine project from another company. When a biotech adds new drugs to work on, watch if they can actually finish testing them.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ACRV1.56

-0.01 (-0.89%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.